The below Parliamentary question was asked by Lord Myners on 2016-04-19.
To ask Her Majesty’s Government what steps they will take to ensure that the liquidity ladder is not used to advantage counterparties of Euronext to the disadvantage of those of LCH Clearnet.
Lord O’Neill of Gatley
I refer the noble Lord to my written answers of 26 April (HL7583, HL7584, HL7585, and HL7586)
The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.
To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.
George Freeman
Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.
|
Number of patients treated in 2011/121 |
Number of patients treated in 2012/131 |
Number of CDF notifications 2013/142 |
Number of CDF notifications 2014/152 |
Number of CDF notifications 2015/16 (to Sept) 2 |
|
|
Peptide receptor radionuclide therapy (to include Lutetium-177 or Yttrium-90 octreotide analogues) |
49 |
117 |
152 |
229 |
116 |
1 Source: Strategic Health Authority returns to the Department of Health
2 Source: NHS England
Information on the number of peptide receptor radionuclide therapy treatments provided outside of the CDF is not collected.
The below Parliamentary question was asked by Craig Whittaker on 2016-07-18.
To ask the Secretary of State for Foreign and Commonwealth Affairs, if his Department will work with (a) Oman and (b) other Middle Eastern countries to broker a deal to end the current conflict in Yemen.
Mr Tobias Ellwood
The Foreign Secretary, my Rt Hon. Friend the Member for Uxbridge and South Ruislip (Mr Johnson), met his Saudi, Emirates and US counterparts on 19 July in London to review the situation in Yemen. A political solution is the best way to bring long-term stability and end the conflict. We welcome and fully support the UN led talks in Kuwait: now is the time to reach an agreement. We will continue to work closely with the UN and partners in the Middle East, including Oman, to encourage both sides to engage constructively.
The below Parliamentary question was asked by Justin Madders on 2016-10-10.
To ask the Secretary of State for Health, what assessment he has made of the likely effect of proposed changes to pharmacy funding on home delivery of NHS prescriptions.
David Mowat
The Government’s proposals for community pharmacy in 2016/17 and beyond, on which we have consulted, are being considered against the public sector equality duty, the family test and the relevant duties of my Rt. hon. Friend, the Secretary of State for Health, under the National Health Service Act 2006.
Our assessments include consideration of the potential impacts on the adequate provision of NHS pharmaceutical services, including the supply of medicines, access to NHS pharmaceutical services, supplementary hours, non-commissioned services, individuals with protected characteristics, impacts on other NHS services, health inequalities, individuals with restricted mobility and access to healthcare for deprived communities.
An impact assessment will be completed to inform final decisions and published in due course.
Our proposals are about improving services for patients and the public and securing efficiencies and savings. We believe these efficiencies can be made within community pharmacy without compromising the quality of services or public access to them.
Our aim is to ensure that those community pharmacies upon which people depend continue to thrive. We are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared with others, considering factors such as location and the health needs of the local population.
We want a clinically focussed community pharmacy service that is better integrated with primary care and public health in line with the Five Year Forward View. This will help relieve the pressure on general practitioners and accident and emergency departments, ensure better use of medicines and better patient outcomes, and contribute to delivering seven day health and care services.
The Chief Pharmaceutical Officer for England, Dr Keith Ridge has commissioned an independent review of community pharmacy clinical services. The review is being led by Richard Murray, Director of Policy at The King’s Fund. The final recommendations will be considered as part of the development of clinical and cost effective patient care by pharmacists and their teams.
NHS England is also setting up a Pharmacy Integration Fund to support the development of clinical pharmacy practice in a wider range of primary care settings, resulting in a more integrated and effective NHS primary care patient pathway.
The rollout of the additional 1,500 clinical pharmacists announced by NHS England will help to ease current pressures in general practice by working with patients who have long term conditions and others with multiple medications. Having a pharmacist on site will mean that patients who receive care from their general practice will be able to benefit from the expertise in medicines that these pharmacists provide.
The below Parliamentary question was asked by Chi Onwurah on 2015-10-28.
To ask the Secretary of State for Culture, Media and Sport, pursuant to the Answer of 27 October 2015 to Question 12790, whether the licence obligation on Telefonica to provide indoor 4G coverage to 98 per cent of UK premises by 2017 includes coverage in tunnels.
Mr Edward Vaizey
The licence obligation on Telefonica to provide indoor 4G coverage to 98% of the UK population by 2017 does not include coverage in tunnels.The Government recognises that dropped calls and intermittent access to the internet are frustrations felt by many rail passengers. The Government is working with the rail and telecommunications industries to reach a collective understanding of the technical and commercial challenges and the potential solution to this problem.
The below Parliamentary question was asked by Holly Lynch on 2015-11-25.
To ask the Secretary of State for Transport, what assessment he has made of the (a) implications for his policies and (b) reasons for the finding of the Civil Service People Survey 2015 that Driver and Vehicle Standard Agency staff rated leadership and management the lowest in the civil service.
Andrew Jones
The Driver and Vehicle Standards Agency (DVSA) acknowledges that its 2015 Civil Service People Survey results are disappointing, and it is determined to improve its leadership and management of change. This is no easy task for an organisation of 4,500 people working across more than 500 sites. It has begun implementing actions to improve staff engagement, including creating forums for specific groups of staff to contribute to change, and Directorate and team meetings focussing specifically on staff engagement. It is also sending out its corporate senior leaders to talk to, and more importantly, to listen to its public-facing operational staff.
The below Parliamentary question was asked by Seema Malhotra on 2015-12-16.
To ask Mr Chancellor of the Exchequer, what recent assessment he has made of the effects on the economy of the level of (a) consumer borrowing and (b) personal loans.
Harriett Baldwin
Household debt as a proportion of income has fallen to 144% in Q2 2015, from a peak of 168% in Q1 2008. To avoid repeating the mistakes of the past we have created the independent Financial Policy Committee (FPC) within the Bank of England to ensure emerging risks and vulnerabilities across the financial system as a whole are identified, monitored and effectively addressed.
The below Parliamentary question was asked by Angela Smith on 2016-01-27.
To ask the Secretary of State for the Home Department, how many times project licence applications were referred to an independent assessor in each year since 2012.
Mr John Hayes
The Harm-Benefit Analysis (HBA) is undertaken, on behalf of the Secretary of State, by the Animals in Science Regulation Unit inspectors, all of whom are veterinary or medically qualified and trained in assessing research proposals. The HBA is the process of considering a research proposal to make a judgement whether the likely harms that the animals will experience are justified by the likely benefits. Under section 18 of the Animals (Scientific Procedures) Act 1986, inspectors advise the Secretary of State who decides whether and on what terms a project licence should be granted.
The number of project licences which were recommended for grant by the Animals in Science Regulation Unit inspectors between 2012 and 2015 are shown in table 1, column (c).
The Secretary of State has not rejected any of the recommendations for granting project licences made by the Animals in Science Regulation Unit inspectors between 2012 and 2015.
The Home Office does not keep records of applications that have been rejected or withdrawn at the concept or drafting stage [24507]. The Home Office does not keep records of which applications were withdrawn as a result of advice from the Animals in Science Regulation Unit inspectors.
The Home Office refers project licence applications to both the Animals in Science Committee and external independent assessors for critical review. The number of project licences referred to both is given in Table 1 columns (a) and (b) respectively for the years 2012-15.
|
Year |
(a) Project licence applications referred to the Animals in Science Committee[1] |
(b) Project licence applications referred to independent assessors |
(c) Project licences granted |
|
2012 |
9 |
4 |
626 |
|
2013 |
3 |
0 |
604 |
|
2014 |
4 |
1 |
474 |
|
2015 |
3 |
0 |
577 |
[1] Prior to 2013 the independent advisory body was entitled the ‘Animals Procedures Committee’
The below Parliamentary question was asked by Mark Durkan on 2016-02-24.
To ask the Secretary of State for Health, what steps his Department is taking to ensure that approved personalised medicines are available to patients with colorectal cancer.
George Freeman
On 24 September, the NHS England Board agreed the development of a Personalised Medicine Strategy for the National Health Service. Personalised medicine is a move away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition. It uses emergent approaches in areas such as diagnostic tests, functional genomic technologies, molecular pathways, data analytics and real time monitoring of conditions to better manage patients’ health and to target therapies to achieve the best outcomes in the management of a patient’s disease or predisposition to disease. The high-level vision and strategy is to create a Personalised Medicine service in the NHS embracing four overarching principles: the prediction and prevention of disease; more precise diagnoses; targeted and personalised interventions; and a more participatory role for patients.
The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Outcomes (July 2015), recommends improvements across the cancer pathway, with the aim of improving survival rates.
NHS England is currently working with partners across the health system to determine how best to take forward the recommendations of the Cancer Taskforce. NHS England has appointed Cally Palmer as National Cancer Director to lead on implementation, as well as new cancer vanguards to redesign care and patient experience. She has set up a new Cancer Transformation Board to implement the strategy, and this met for the first time on Monday 25 January. There will also be a Cancer Advisory Group, chaired by Sir Harpal Kumar, to oversee and scrutinise the work of the Transformation Board.
The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for NHS patients to transformative new medicines and technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include personalised medicines for the treatment of colorectal cancer.
The below Parliamentary question was asked by Royston Smith on 2016-03-21.
To ask the Secretary of State for Energy and Climate Change, what steps her Department is taking to ensure that the UK meets its renewed target of zero carbon emissions by 2050.
Andrea Leadsom
The Government believes we will need to take the step of enshrining the global goal of net zero greenhouse gas emissions in the second half of the century, agreed in Paris, into UK law. The question is not whether but how we do it.
The Government also remains committed to its existing Climate Change Act target of an at least 80% reduction in greenhouse gas emissions by 2050 on 1990 levels. Our working assumption is that we will publish our Emissions Reduction Plan by the end of 2016, which will set out our proposals for meeting our Climate Change Act targets.